Business context and reporting period
This filing is Trxade Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, comparing FY2020 with FY2019; it does not report Q4-only results. The request identifies Scienture Holdings, Inc., but the filing names Trxade Group, Inc. (Nasdaq: MEDS). Confirm the issuer before relying on this summary.
Trxade operates an online pharmaceutical marketplace, a pharmaceutical wholesaler through Integra, and a specialty pharmacy through Community Specialty Pharmacy. FY2020 revenue growth was strongly influenced by Integra’s sales of COVID-related PPE products.
Key financial metrics
| Metric | FY2020 / December 31, 2020 | FY2019 / December 31, 2019 |
|---|---|---|
| Revenue | $17.12 million | $7.44 million |
| Gross profit | $5.71 million; 33% gross margin | $4.87 million; 66% gross margin |
| Operating loss | $2.51 million | Operating income of $125,224 |
| Net loss | $2.54 million; $0.33 per diluted share | $284,428; $0.05 per diluted share |
| Cash from operations | $(2.21) million | $141,775 |
| Cash from investing | $(37,505) | $(332,252) |
| Cash from financing | $5.30 million | $2.19 million |
| Cash and cash equivalents | $5.92 million | $2.87 million |
| Working capital | $8.38 million | $3.28 million |
| Total liabilities | $1.11 million | $1.43 million |
Revenue rose 130.3%, while cost of sales increased 345.0%, principally as PPE sales expanded. Marketplace revenue grew 23% to $5.55 million; Integra revenue rose to $9.88 million from $1.02 million; specialty pharmacy revenue declined to $1.65 million from $1.89 million. The filing attributes the lower gross margin to PPE’s higher cost of sales and the larger share of marketplace revenue in 2019, which carries no cost of sales.
FY2020 included a $1.22 million inventory write-down and a $725,973 goodwill impairment. General and administrative costs and stock-based compensation also increased; the filing reports $1.86 million of warrants-and-options expense in its MD&A results table. The company raised approximately $5.99 million gross in a February 2020 underwritten stock offering, with net proceeds described in different sections as approximately $5.17 million and approximately $5.3 million.
Material changes, outlook and risks
- Operating cash flow turned negative, principally reflecting PPE inventory purchases and deposits. Year-end inventory was $1.26 million, versus $56,761 a year earlier; other receivables were $1.09 million, primarily related to undelivered glove orders.
- Debt at year-end was $225,000, a related-party note bearing 10% interest and due October 15, 2021. The company reported no traditional bank credit facility. Operating lease liabilities totaled $402,459.
- Management said available cash and expected operating revenue should support operations at then-current levels for the next 12 months, while estimating 2021 operating expenses and working capital needs of approximately $8 million. It may seek additional debt or equity to fund expansion or acquisitions; financing availability and terms are uncertain. No specific revenue or earnings guidance was provided.
- COVID-19 had not materially reduced reported revenue or gross profit through the filing date, according to management, but caused supply interruptions, delivery delays, price volatility and inventory write-down risk. Bonum Health Hub installations were deferred until at least later in 2021, and several telehealth and health-passport offerings had not generated revenue.
- Two customers represented 25% and 15% of FY2020 revenue, creating material customer-concentration exposure. The company also depends on suppliers and third-party contracts and faces pharmaceutical licensing, pricing, privacy, fraud-and-abuse, and other regulatory risks.
- Two glove-related deposits totaling approximately $1.08 million remained in dispute: $500,000 with Studebaker and $581,250 connected to Crecom. The company had filed lawsuits and expected recovery, but outcomes and collection were uncertain. A separate federal complaint sought approximately $450,000; the company assessed the likelihood of a material loss as remote.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end and identified material weaknesses, including inadequate written accounting procedures, reporting controls, financial systems and segregation of duties. Remediation was ongoing. The auditor issued an unmodified opinion on the financial statements but did not audit or opine on internal control effectiveness.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Trxade Group, Inc., not Scienture Holdings, Inc.
- Reconcile the offering’s reported net proceeds and compare operating cash burn with management’s stated 12-month liquidity outlook and approximately $8 million 2021 expense estimate.
- Track collection of the $1.08 million disputed deposits, including court outcomes, recoverability and any resulting impairment or cash receipts.
- Assess whether PPE-driven revenue and margins are repeatable, and monitor inventory write-downs, customer concentration and supplier availability.
- Review remediation of the disclosed internal-control material weaknesses and potential dilution from outstanding options, warrants or future financing.